# A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

> **NCT04187404** · PHASE1,PHASE2 · TERMINATED · sponsor: **Enterome** · enrollment: 70 (actual)

## Conditions studied

- Adrenocortical Carcinoma
- Pheochromocytoma
- Paraganglioma

## Interventions

- **BIOLOGICAL:** EO2401
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT04187404
- **Lead sponsor:** Enterome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-23
- **Primary completion:** 2024-10-02
- **Final completion:** 2024-10-02
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Strategic decision
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04187404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04187404, "A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04187404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*